Literature DB >> 18642403

A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain.

John Whitehead1, Elsa Valdés-Márquez, Agneta Lissmats.   

Abstract

Two-stage designs offer substantial advantages for early phase II studies. The interim analysis following the first stage allows the study to be stopped for futility, or more positively, it might lead to early progression to the trials needed for late phase II and phase III. If the study is to continue to its second stage, then there is an opportunity for a revision of the total sample size. Two-stage designs have been implemented widely in oncology studies in which there is a single treatment arm and patient responses are binary. In this paper the case of two-arm comparative studies in which responses are quantitative is considered. This setting is common in therapeutic areas other than oncology. It will be assumed that observations are normally distributed, but that there is some doubt concerning their standard deviation, motivating the need for sample size review. The work reported has been motivated by a study in diabetic neuropathic pain, and the development of the design for that trial is described in detail. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18642403     DOI: 10.1002/pst.341

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  7 in total

1.  Adaptive designs for comparative effectiveness research trials.

Authors:  John A Kairalla; Christopher S Coffey; Mitchell A Thomann; Ronald I Shorr; Keith E Muller
Journal:  Clin Res Regul Aff       Date:  2014-11-13

2.  Group sequential clinical trial designs for normally distributed outcome variables.

Authors:  Michael J Grayling; James M S Wason; Adrian P Mander
Journal:  Stata J       Date:  2018-06-01       Impact factor: 2.637

3.  Optimal multistage designs for randomised clinical trials with continuous outcomes.

Authors:  James M S Wason; Adrian P Mander; Simon G Thompson
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

4.  Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes.

Authors:  James M S Wason; Adrian P Mander
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

5.  Group sequential designs for stepped-wedge cluster randomised trials.

Authors:  Michael J Grayling; James Ms Wason; Adrian P Mander
Journal:  Clin Trials       Date:  2017-06-27       Impact factor: 2.486

6.  Group sequential crossover trial designs with strong control of the familywise error rate.

Authors:  Michael J Grayling; James M S Wason; Adrian P Mander
Journal:  Seq Anal       Date:  2018-10-02       Impact factor: 0.927

7.  Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial.

Authors:  Martin P Paulus; Rayus Kuplicki; Teresa A Victor; Hung-Wen Yeh; Sahib S Khalsa
Journal:  BMC Psychiatry       Date:  2021-11-19       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.